Join Paid Clinical Trials for COPD in

Paid Clinical Trials and Focus Groups


Find Paid Clinical Trials

Paid Clinical Trials - : COPD

Top of Directory » All Categories » by Illness » COPD



  • Symptom Clusters and Immune Markers in Patients With Chronic Obstructive Pulmonary Disease (COPD) - a Longitudinal Study

    Condition:   Chronic Obstructive Pulmonary Disease
    Intervention:  
    Sponsors:   Rikshospitalet HF;   University of California, San Francisco
    Not yet recruiting - verified November 2009
  • Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD)

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Fosinopril;   Other: lactose
    Sponsors:   Imperial College London;   Medical Research Council
    Recruiting - verified November 2009
  • A Descriptive Study to Explore Certain Characteristics of Patients at Risk for Chronic Obstructive Pulmonary Disease (COPD) in a Primary Care Setting

    Condition:   Chronic Obstructive Pulmonary Disease
    Intervention:  
    Sponsor:   AstraZeneca
    Recruiting - verified November 2009
  • Effect of Indacaterol on Inspiratory Capacity (IC)

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Indacaterol;   Drug: Tiotropium;   Drug: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified November 2009
  • Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: MN-221 (Dose Group 1);   Drug: MN-221 (Dose Group 2);   Drug: MN-221 (Dose Group 3)
    Sponsor:   MediciNova
    Recruiting - verified November 2009
  • A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

    Condition:   Pulmonary Disease, Chronic Obstructive
    Interventions:   Drug: GW642444 Inhalation Powder;   Drug: FF/GW642444 Inhalation Powder
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009
  • A Study of CellCept (Mycophenolate Mofetil) in Lung Transplant Recipients

    Condition:   Lung Transplantation
    Intervention:   Drug: mycophenolate mofetil [CellCept]
    Sponsor:   Hoffmann-La Roche
    Not yet recruiting - verified November 2009
  • A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease

    Condition:   COPD
    Intervention:   Drug: R7103
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • Factors Determining Quality of Life Related to Respiratory Status According to Gender of Chronic Obstructive Pulmonary Disease (COPD) Patients

    Condition:   Chronic Obstructive Pulmonary Disease
    Intervention:  
    Sponsor:   AstraZeneca
    Recruiting - verified November 2009
  • A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Glycopyrronium bromide;   Drug: Placebo
    Sponsor:   Novartis
    Recruiting - verified November 2009
  • Reducing Dynamic Hyperinflation Through Breathing Retraining

    Condition:   Pulmonary Disease, Chronic Obstructive
    Interventions:   Other: breathing retraining;   Other: exercise training
    Sponsor:   Department of Veterans Affairs
    Recruiting - verified November 2009
  • Spiriva Observational Study Measuring SGRQ in Routine Medical Practice in Central & Eastern European Region

    Condition:   Chronic Obstructive Pulmonary Disease
    Intervention:  
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Not yet recruiting - verified October 2009
  • Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Aclidinium bromide;   Drug: Placebo
    Sponsors:   Almirall S.A.;   Forest Laboratories
    Recruiting - verified November 2009
  • Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Indacaterol;   Drug: Tiotropium
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified October 2009
  • Study of the Effects of SCH 527123 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (Protocol No. P05575)

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: SCH 527123;   Drug: Placebo
    Sponsor:   Schering-Plough
    Recruiting - verified November 2009
  • Macrolide Maintenance Therapy in Chronic Obstructive Pulmonary Disease (COPD)

    Condition:   COPD
    Interventions:   Drug: Azithromycin;   Drug: Placebo
    Sponsors:   Amphia Hospital;   Erasmus Medical Center;   Stichting Solong
    Not yet recruiting - verified November 2009
  • GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease

    Conditions:   Chronic Bronchitis;   Chronic Obstructive Pulmonary Disease (COPD);   Emphysema
    Interventions:   Drug: 125mcg twice-daily;   Drug: 1000mcg once-daily;   Drug: 125mcg once-daily;   Drug: 250mcg once-daily;   Drug: 250mcg twice-daily;   Drug: 500mcg once-daily;   Drug: 62.5mcg once-daily;   Drug: 62.5mcg twice-daly;   Drug: Placebo;   Drug: Tiotropium
    Sponsor:   GlaxoSmithKline
    Recruiting - verified October 2009
  • 1-year Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Chronic Obstructive Pulmonary Disease (COPD)

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: NVA237;   Drug: Placebo to NVA;   Drug: Tiotropium
    Sponsor:   Novartis
    Recruiting - verified November 2009
  • Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Arformoterol;   Drug: Placebo
    Sponsor:   Sepracor, Inc.
    Recruiting - verified October 2009
  • A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Indacaterol;   Drug: Tiotropium
    Sponsor:   Novartis
    Recruiting - verified November 2009
  • Comparison of Indacaterol and Tiotropium on Lung Function and Related Outcomes in Patients With Chronic Obstructive Pulmonary Disease (COPD)

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Indacaterol 150 µg;   Drug: Tiotropium
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified November 2009
  • Effectiveness of Long-term Oxygen Therapy in Treating People With Chronic Obstructive Pulmonary Disease (The Long-term Oxygen Treatment Trial [LOTT])

    Condition:   Chronic Obstructive Pulmonary Disease
    Intervention:   Behavioral: Supplemental oxygen therapy
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Centers for Medicare and Medicaid Services
    Recruiting - verified October 2009
  • Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD

    Conditions:   COPD;   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: BIO-11006 Inhalation Solution;   Drug: BIO-11006 Inhalation Solution;   Drug: BIO-11006 Inhalation Solution;   Drug: Placebo;   Drug: BIO-11006
    Sponsors:   BioMarck Pharmaceuticals, Ltd.;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified June 2009
  • Fresh Air-Safety, Effectiveness of Spiriva in Patients With COPD in Multicentres

    Condition:   Pulmonary Disease, Chronic Obstructive
    Intervention:  
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Recruiting - verified October 2009
  • A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).

    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: PH-797804;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting - verified November 2009
    • Menu
    Find Paid Clinical Trials